Global Thalassemia Treatment Market, By Type (Alpha-thalassemia, Beta Thalassemia), Treatment (Blood Transfusions, Iron Chelation Therapy, Folic Acid Supplements, Gene Therapy, Bone Marrow Transplants), End User (Hospitals and Clinics, Diagnostic Laboratories and Others), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East & Africa) Industry Trends and Forecast to 2028
Market Analysis and Insights : Global Thalassemia Market
The thalassemia market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing with the CAGR of 16% in the forecast period of 2021 to 2028. The growing number of clinical trials for the treatment options for thalassemia will help in escalating the growth of the thalassemia market.
Thalassemia is a blood disorder that leads to abnormal production of haemoglobin in an affected person. It is a hereditary disorder inherited from parents. Patients with insufficient haemoglobin also suffer from thalassemia. Thalassemia is caused by any abnormality or mutation in one or more genes accountable for the production of haemoglobin. When a person acquires from only one affected gene from the parents then the person becomes a carrier of thalassemia. Because thalassemia is a hereditary disorder; one of the parents must be a bearer for thalassemia. When both the parents are the bearers then the danger of giving birth to a thalassemia affected infant is quite high. Thalassemia is usually of two categories: alpha thalassemia and beta thalassemia.
The growing prevalence of thalassemia is projected to boost the growth of the thalassemia market. The growing of the pipeline drugs in thalassemia is anticipated to propel the growth of the thalassemia market. Factors such as the increasing market of bone marrow transplant and blood transfusion therapy, along with the large numbers of transfusion dependent patients, the increase in the realisation related to accessible treatment solutions for the treatment of thalassemia is expected to drive the growth of the thalassemia market. additionally, the increase in the need for improvised curative gene therapy, increasing of incidences of thalassemia, growing population, escalating healthcare spending, rising expenditure on pharmaceuticals research and development and stem cell therapy research are few of the factors further expected to cushion the growth of the thalassemia market in the forecast period. The main aim of this market involves advancing of drug pipeline, increasing opportunity for gene therapy and rising knowledge towards thalassemia. Despite that, there are few factors which can hamper growth of the thalassemia market along with administrating adjustments, coupled risks and high cost of treatment.
This thalassemia market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographical expansions, technological innovations in the market. To gain more info on thalassemia market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
Thalassemia Market Scope and Market Size
The thalassemia market is segmented on the basis of type, treatment and end user. The growth amongst these segments will help you analyse meagre growth segments in the industries and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.
- Based on the type, the thalassemia market is segmented into alpha-thalassemia, beta thalassemia.
- Based on the treatment, the thalassemia market is segmented into blood transfusions, iron chelation therapy, folic acid supplements, gene therapy, bone marrow transplants.
- Based on the end user, the thalassemia market is segmented into hospitals and clinics, diagnostic laboratories and others.
Thalassemia Market Country Level Analysis
The thalassemia market is analysed and market size insights and trends are provided by country, type, treatment and end user as referenced above.
The countries covered in the thalassemia market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
North America dominates the thalassemia market because of the growing knowledge about thalassemia and increasing government efforts to support gene therapy. Also because of the advancing of the drug pipeline which is further expected to boost the growth of the thalassemia market in the region. Asia-Pacific is anticipated to observe significant amount of growth because of the extreme heterogeneity, an irregular frequency of thalassemia heterozygote or carrier Furthermore, government and many other organizations are working to form consciousness amongst the population.
The country section of the thalassemia market report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import export analysis, price trend analysis, cost of raw materials, down-stream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Healthcare Infrastructure growth Installed Base and New Technology Penetration
The thalassemia market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for healthcare analytical testing services market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the thalassemia market. The data is available for historic period 2011-2019.
Competitive Landscape and Thalassemia Market Share Analysis
The thalassemia market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to thalassemia market.
The major players covered in the thalassemia market report are ApoPharma Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd.; Fresenius Kabi AG; Pfizer Inc.; bluebird bio, Inc.; Acceleron Pharma, Inc.; Incyte; Kiadis Pharma; Gamida Cell; CELGENE CORPORATION; GlaxoSmithKline plc; Ionis Pharmaceuticals, Inc.; Vifor Pharma; La Jolla Pharmaceutical Company; Lonza., and Sangamo Therapeutics; among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.
SKU-